

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No: L24239MH1987PLC043662

**Date: 13<sup>th</sup> April, 2023**

**To,**  
**The Deputy General Manager**  
The Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

**Subject: Submission of Reconciliation of Share Capital Audit Report as required under Regulation 76 of SEBI (Depositories and Participants) Regulation, 2018 for quarter ended March 31, 2023**

**Dear Sir / Madam,**

In compliance with Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder "**Reconciliation of Share Capital Audit Report**" for the quarter ended March 31, 2023; as issued by CS Kala Agarwal, Practicing Company Secretary.

Kindly take this information on record.

Yours faithfully,

**For Fredun Pharmaceuticals Limited**

JINKAL  
SUNNY SONI

Digitally signed by  
JINKAL SUNNY SONI  
Date: 2023.04.13  
13:17:24 +05'30'

**Jinkal Soni**  
**(Jinkal Shah)**  
**Company Secretary and Compliance Officer**  
**Membership No. A40722**

Encl.: As above

**Registered Office:** Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)  
**Corporate Office:** Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

**Phone No.:** 91-22- 4031 8111 **Fax:** 91-22-4031 8133

**Factory:** 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

**Phone No.:** +917045957828, +917045957829, +917045957830, +917045956857

**E-Mail:** business@fredungroup.com **Web:** www.fredungroup.com





801, Embassy Centre, Plot No. 207, Jamnalal Bajaj Road, Nariman Point, Mumbai - 400 021.

Tel: +91-22-22824639 / 22824659 / 7021597117 / 9137774259

Mob: + 91-9819888185 • E-mail: agarwalkala@gmail.com / admin@kalaagarwal.com

[www.kalaagarwal.com](http://www.kalaagarwal.com)

**RECONCILIATION OF SHARE CAPITAL AUDIT REPORT**  
**{As per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018}**

1.	For Quarter Ended	:	March 31, 2023
2.	ISIN	:	INE194R01017
3.	Face Value	:	Equity Share Rs. 10/- (Rupees Ten Only)
4.	Name of the Company	:	Fredun Pharmaceuticals Limited
5.	Registered Office Address	:	11 <sup>th</sup> Floor, Tower A, Urmi Estate 95, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai- 400013.
6.	Correspondence Address	:	11 <sup>th</sup> Floor, Tower A, Urmi Estate 95, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai- 400013.
7.	Telephone & Fax No.	:	Phone: 022-40318111 Fax No. 022-40318133
8.	Email Address	:	<a href="mailto:business@fredungroup.com">business@fredungroup.com</a>
9.	Name of the stock exchange where company's securities are listed	:	BSE Limited
10.	Issued Capital	:	45,32,272 Equity Shares of Rs. 10/- each fully paid-up aggregating to Rs. 4,53,22,720/-.

Reconciliation of Share Capital Audit Report of Fredun Pharmaceuticals Limited for the period ended 31.03.2023



Page 1 of 3

11.	Listed Capital (Exchange-wise) (as per Company's record)	:	45,32,272 Equity Shares of Rs. 10/- each fully paid-up aggregating to Rs. 4,53,22,720/-.				
			<b>No. of Equity Shares</b>		<b>Percentage (%)</b>		
12.	Held in dematerialized form in CDSL	:	14,02,561		30.95 %		
13.	Held in dematerialized form in NSDL	:	30,24,641		66.73 %		
14.	Physical	:	1,05,070		2.32 %		
15.	<b>Total No. of Shares (12+13+14)</b>	:	<b>45,32,272</b>		<b>100.00 %</b>		
16.	Reason for difference if any, between (10 & 11), (10 &15), (11 & 15)	:	N.A.				
17.	Certifying the details of changes in share capital during quarter under consideration as per table below:						
Particulars ***		No of shares	Applied /Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether Intimated to NSDL	In-principal appr, pending for SE (Specify Names)
Preferential Issue		17,500	Applied	BSE Limited	Yes	Yes	No

\*\*\*Rights, Bonus, Preferential Issue, ESOP's, Amalgamation, Conversion, Buy Back, Capital Reduction, Forfeiture, any other (to specify)

18.	Register of Members is updated (Yes / No):	:	Yes
19.	Reference to previous quarter with regards to excess dematerialization of shares, if any	:	N.A.
20.	Has the company resolved the matter mentioned in point no: 19 above in the current quarter.	:	N.A.





21.	Mention the total no. of request, if any:
-----	---

Requests	No. of Request	No. of Shares	Reason for Delay
Confirmed after 21 days	Nil	Nil	Nil
Pending for more than 21 days	Nil	Nil	Nil
22.	Name, Telephone & Fax No. of the Compliance officer of the Co.	:	<b>Ms. Jinkal Shah</b> Telephone: (022) 40318111
23.	Name, Address, Tel & Fax no. Registration no. of the Auditor	:	<b>Ms. Kala Agarwal</b> Practising Company Secretary 801, Embassy Center, Jamnalal Bajaj Road, Nariman Point, Mumbai - 400 021 Tel.: 022-22824659, CP.NO. 5356 Membership No. 5976
24.	Appointment of common agency for share registry work if yes (Name & address)	:	<b>Purva Sharegistry (India) Private Limited</b> 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg, Lower Parel, Mumbai- 400011 Tel No. 022-23012518
25.	Any other details that the auditor may like to provide. (E.g. BIFR Company, delisting from SE, company changed its name etc.)	:	Not Applicable

  
**KALA AGARWAL**  
 Practising Company Secretary  
 C.P. No. 5356  
 UDIN: F005976E000081678



Place: Mumbai  
 Date: 13<sup>th</sup> April, 2023